Chad Lewis

Chad Lewis has worked in a variety of roles since 2010. Chad began as an Assistant Professor at Cornell University in 2010, followed by a role as a Senior Principal Scientist and Principal Scientist at Pfizer from 2015-2020. In 2020, they became an Associate Director of Chemistry at FogPharma, and in 2021 they became the Director of Chemistry and Manufacturing at K36 Therapeutics, Inc.

Chad Lewis has a long and impressive educational history. Chad began their academic career by earning a Bachelor of Science in Chemistry with Honors from the University of Alberta between 1997 and 2002. Chad then attended Boston College from 2003 to 2006, studying Chemistry without obtaining a degree. After that, they earned a Doctor of Philosophy (Ph.D.) in Chemistry from Yale University between 2005 and 2008. Chad then became a Postdoctoral Scholar at The Scripps Research Institute from 2008 to 2010, studying Total synthesis of marine natural products. Most recently, they are pursuing a Masters in Business Administration in Financial Management at Marist College School of Management, which they began in 2020 and is expected to complete in 2023.